Peter Dudek, PhD, has over 13 years’ experience in the life sciences industry spanning research, company building, as well as corporate and traditional venture capital, across a broad range of therapeutic areas and modalities.
He currently serves as President and Managing Partner of Merck’s MRL Ventures Fund and is responsible for its investments in Carisma, Hotspot, Kymera (NASDAQ: KYMR), Imago, Xilio, and Caraway Therapeutics. Prior to MRLV, he was a Principal with Wellington Partners, a Munich and London based European venture fund with more than $1B under management and was involved in investments across a broad range of life science companies including Middle Peak Medical (sold to Symetis/Boston Scientific), Atopix (sold to Chiesi), Optinose (NASDAQ:OPTN), Prosonix (sold to Circassia), iOmx, Imevax, Oxagen and Vasopharm. Before this he held roles at Entrepreneurs Fund and at the corporate venture arm of Novartis.
Dr. Dudek holds a Bachelor of Science with Honors from the University of British Columbia, obtained his PhD from the University of Geneva, and was a postdoctoral fellow at the University of Oxford.